Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


May 22, 2001 22 May, 2001

Pheromone Sciences Pivotal Trial Patient Recruitment Underway Results Expected During Q-4


Pheromone Sciences Corp (CDNX: PHS), today announced that patient recruitment has commenced on schedule at the U.S. based multi-center efficacy trial of its PSC Fertility Monitor(tm).

The trial, to be carried out in 140 subjects, is taking place at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Patient interest at both trial centers has been high with results expected during Q-4, 2001.

"We are very pleased that the interest to participate in this trial is so strong within our community ", commented Duke University's Dr. Arthur Haney, Professor of Obstetrics and Gynecology. "As a non-invasive device that provides users with the opportunity to carry out home testing without urine or blood samples, the PSC Fertility Monitor offers a new level of convenience".

The U.S. study follows on the heels of the positive clinical results previously reported from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial demonstrated that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favorably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

"We remain committed to our goal of completing this trial for the fall using the results to underpin submissions to the FDA for marketing approval prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "Positive results would pave the way for U.S. regulatory approval and subsequent commercialization".

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.